Menu
A pilot study was designed to determine whether the use of ACT™ would have any benefit for Peak expiratory flow. Peak flow is a quick test to measure air flowing out of the lungs.
15 subjects ages ranging from 42-76 were selected. Subjects with existing respiratory illness were excluded.
Subjects were given two 20 minute sessions of ACT™ per week for 8 weeks. They were measured for peak flow at baseline, four and eight weeks.
Users simply blow into a peak flow meter which is a small hand-held device used to monitor a person’s ability to breathe out air.
The results of this pilot study showed an increase in peak flow after 8 weeks in all but 1 of the 15 subjects. A further study with a larger population size and additional quantitative outcomes is being undertaken.
Additional benefits noted by the study group were reduced stress, and enhanced focus and energy.
There were no negative side effects reported. For more detailed information contact [email protected]
Arch Systems, LLC has developed and patented a method that is designed to improve Respiratory Health and Well Being.
This product is not intended to “diagnose, treat, or cure any disease”